Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

QRX003

Rare Disease news

Rare Diseases Today—June 4, 2026

This week’s Rare Disease update highlights regulatory milestones, late-stage…

Rare Disease news

Rare Diseases Today—March 19, 2026

This week’s Rare Diseases update highlights regulatory momentum, clinical…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Vida Health and Instacart Health Partner on Fresh Funds | Lucid Diligence Brief
Ascidian and Lilly $1.9B Deal for Kidney RNA Editing | Lucid Diligence Brief
IDEAYA and Roche Collaboration | Lucid Diligence Brief
Cell and Gene Therapy Today—June 4, 2026
Cardiovascular Today—June 4, 2026

Tags

AIR-001 Allogene Therapeutics AMT-130 Apple Watch Hypertension Applied Therapeutics ATM-negative mCRC Brexu-cel care coordination CLEVER Cobas MPX-E CRO market DESTINY-Breast09 deupirfenidone Duke Health Earendil Labs Elecsys NfL Excellergy FXa DOAC Gan & Lee Pharmaceuticals Genprex GRADE Heart failure with preserved ejection fraction HES MeiraGTx menin inhibitor METTL3 MVC NHS fetal anomaly AI OGT OSENVELT polymyalgia rheumatica Servier SIR-Spheres Skye Biosciences Sleep and Cardiovascular Risk TGF beta Third-Line Non-Small Cell Lung Cancer transcriptomics Tuberculosis Meningitis TUZEMTY University Of Pennsylvania US Heart & Vascular Wearable Biomarkers withZeta.ai Zorpocabtagene Autoleucel

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Vida Health and Instacart Health Partner on Fresh Funds | Lucid Diligence Brief
Ascidian and Lilly $1.9B Deal for Kidney RNA Editing | Lucid Diligence Brief
IDEAYA and Roche Collaboration | Lucid Diligence Brief
Cell and Gene Therapy Today—June 4, 2026
Cardiovascular Today—June 4, 2026

TAGS

AIR-001 Allogene Therapeutics AMT-130 Apple Watch Hypertension Applied Therapeutics ATM-negative mCRC Brexu-cel care coordination CLEVER Cobas MPX-E CRO market DESTINY-Breast09 deupirfenidone Duke Health Earendil Labs Elecsys NfL Excellergy FXa DOAC Gan & Lee Pharmaceuticals Genprex GRADE Heart failure with preserved ejection fraction HES MeiraGTx menin inhibitor METTL3 MVC NHS fetal anomaly AI OGT OSENVELT polymyalgia rheumatica Servier SIR-Spheres Skye Biosciences Sleep and Cardiovascular Risk TGF beta Third-Line Non-Small Cell Lung Cancer transcriptomics Tuberculosis Meningitis TUZEMTY University Of Pennsylvania US Heart & Vascular Wearable Biomarkers withZeta.ai Zorpocabtagene Autoleucel

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy